Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 30/100

Failure Rate

10.0%

1 terminated/withdrawn out of 10 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

50%

5 trials in Phase 3/4

Results Transparency

200%

2 of 1 completed trials have results

Key Signals

6 recruiting2 with results

Enrollment Performance

Analytics

Phase 3

4(66.7%)

Phase 4

1(16.7%)

Phase 2

1(16.7%)

6Total

Phase 3(4)

Phase 4(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT06679270Phase 3Recruiting

Open-label Extension Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy

Role: lead

NCT06502990Phase 3Recruiting

Open-label Study to Evaluate Metreleptin in Children Under 6 Years of Age With Generalised Lipodystrophy

Role: lead

NCT02325674Recruiting

MEASuRE: Metreleptin Effectiveness And Safety Registry

Role: lead

NCT06423573Recruiting

A Study to Assess the Incidence of Skin Cancers in Patients With Epidermolysis Bullosa Receiving Filsuvez

Role: lead

NCT05164341Phase 3Active Not Recruiting

Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PL

Role: lead

NCT04681170Phase 3Completed

Efficacy and Safety of Lomitapide in Paediatric Patients With Homozygous Familial Hypercholesterolaemia (HoFH)

Role: lead

NCT06484868Phase 4Recruiting

Open-label Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy

Role: lead

NCT05351164Phase 2Active Not Recruiting

Evaluation of Safety and Efficiency of Metreleptin Treatment for Patients With Multiple Symmetric Lipomatosis (MSL)

Role: collaborator

NCT02135705Recruiting

LOWER: Lomitapide Observational Worldwide Evaluation Registry

Role: lead

NCT02399839Terminated

Global Lomitapide Pregnancy Exposure Registry

Role: lead

All 10 trials loaded